RenovaroCube unveils Flamingo AI model for early multi-cancer detection via fragmentomics

Lunai Bioworks Inc.

Flamingo uses ultra-low pass WGS of cfDNA; requires as few as 200,000 fragments per sample.
Model integrates fragment lengths, sequence motifs, and neural network to distinguish cancer vs. healthy.
Part of The Cube platform, combining multi-omic data for comprehensive early detection and monitoring.
RenovaroCube is wholly owned by Renovaro (Nasdaq: RENB); Cyclomics acquisition previously announced.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.